Cambridge NeuroScience, Boehringer Ingelheim Corp. deal

Boehringer Ingelheim will invest $10 million in CNSI through the purchase of 1.2 million shares at $8.08, based on the clinical progress of CNSI's Cerestat NMDA ion-channel blocker. CNSI started a piv...